Metformin attenuated sepsis-associated liver injury and inflammatory response in aged mice

Heng Song\textsuperscript{a,b,#}, Xiaojuan Zhang\textsuperscript{a,b}, Ruiqing Zhai\textsuperscript{c}, Huoyan Liang\textsuperscript{a,b}, Gaofei Song\textsuperscript{a,b}, Yangyang Yuan\textsuperscript{a}, Yanan Xu\textsuperscript{a}, Yan Yan\textsuperscript{a}, Lingxiao Qiu\textsuperscript{d}, and Tongwen Sun\textsuperscript{a,b}

\textsuperscript{a}General ICU, The First Affiliated Hospital of Zhengzhou University, Henan Key Laboratory of Critical Care Medicine, Zhengzhou Key Laboratory of Sepsis, Henan Engineering Research Center for Critical Care Medicine, Zhengzhou, China; \textsuperscript{b}Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China; \textsuperscript{c}College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China; \textsuperscript{d}Department of Respiratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

ABSTRACT

Sepsis-associated liver injury is with poor survival in intensive care units. Metformin is well known for its therapeutic effects; however, its impact on treating liver injury due to sepsis remains poorly understood. This study investigated the therapeutic effects of metformin on aged mice suffering from sepsis-associated liver injury. Male C57BL/6 J mice aged (18–19 months) were divided into 3 groups: 1) intraperitoneal injection of sterile normal saline (C group), 12.5 mg/kg lipopolysaccharide (LPS) to induce sepsis-associated liver injury (LPS group), and 25 mg/kg metformin (MET) at 1 h after LPS injection (MET group). After 24 h, blood samples and liver tissue were collected for biochemical analysis. Histological assays revealed significantly elevated inflammatory infiltration and apoptosis in the liver, while metformin was found to relieve these aberrant features. The percentage of apoptotic cells decreased after metformin treatment ($P < 0.05$). Additionally, MET group had significantly reduced plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels compared to the LPS group ($P < 0.05$). Furthermore, in the MET group, the mRNA levels of chemokines and inflammatory factors, TNF-$\alpha$, IL-6, caspase-1, decreased markedly ($P < 0.05$). Metformin notably reversed the decreased phosphorylated AMP-activated protein kinase (p-AMPK) and PGC-1$\alpha$ expressions in the liver of septic rats. Metformin also inhibited PDK1, HIF-1$\alpha$ expression, including downstream inflammatory mediators, HMGB1 and TNF-$\alpha$. Metformin attenuated inflammation and liver injury in septic aged mice. Most importantly, we report the effect of metformin on liver injury via the AMPK–PGC1$\alpha$ axis in septic aged mice for the first time.

CONTACT Tongwen Sun \texttt{suntongwen163.com} General Intensive Care Unit (ICU), The First Affiliated Hospital of Zhengzhou University, Henan Key Laboratory of Critical Care Medicine, Zhengzhou Key Laboratory of Sepsis, Henan Engineering Research Center for Critical Care Medicine, 1 Jianshe East Road, Zhengzhou 450052, China

\#Equally contributed to this article.

\textsuperscript{©} 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
**Introduction**

Sepsis is a life-threatening organ dysfunction caused by the dysregulated host response to infection [1], frequently resulting in disability and death [2]. It affects one-third of patients admitted to intensive care units (ICU), with an estimated mortality rate of 25–35% [3]. Strikingly, the incidence of sepsis in the elderly is relatively high. More than half of sepsis patients are 65 years and older [4–6]. Additionally, sepsis in older patients has a worse outcome, with higher rates of mortality, disability, long-term hospitalization, and severe organ dysfunction [7–9]. The pathogenesis and vital organ injury (especially the liver injury) due to sepsis leading to death are not fully understood. Moreover, there are hardly any effective sepsis-treatment strategies [10–12]. Therefore, it is urgent to explore new effective therapies to attenuate sepsis-induced inflammation and liver injury.

Metformin has long been a first-line drug treating type 2 diabetes, and in recent decades it was found to have a wide range of non-hypoglycemic effects, including anti-tumor, anti-inflammatory, anti-aging, and anti-microbial effects [13–16]. Potential mechanisms for metformin to exert these effects include increased AMPK activity and anti-reactive oxygen species effects, thereby reducing chronic inflammation and oxidative damage accumulation [17]. Metformin can also prevent the onset and progression of sepsis by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) directly, independent of the AMPK-pathway activation [18], and thus exert an anti-inflammatory effect [19]. Additionally, metformin can protect lung tissue from oxidative injury induced by sepsis [20]. Our previous review also showed that before-admission metformin use was associated with lower mortality in adult septic patients with diabetes mellitus [21]. However, the role of metformin on inflammation during sepsis has not been studied in aged mice. This study is the first to investigate the effects of metformin on sepsis-induced liver injury in aged mice and decipher the possible mechanisms, which may provide a potential therapy for sepsis. In the present study we hypothesized that metformin may alleviate liver injury in aged septic mice by activating AMPK and thus upregulating PGC1α. We investigated the therapeutic effects of metformin on aged mice suffering from sepsis-associated liver injury.

**Materials and methods**

**Construction of sepsis model**

Thirty adult male C57BL/6 J mice (each weighing 30–40 g, 18 months old) were purchased from Charles River (Beijing, China). The experimental mice were housed in standard cages at a constant ambient temperature and humidity (22 ± 2°C, 40–60%, n = 5 per cage) and kept under a twelve-hour light/dark cycle with free food and drinking. Experiments were conducted after 1 week of acclimatization of the mice to the environment. The experimental animals were randomly divided into three groups (n = 10/group): physiological saline was injected intraperitoneally as control (C group); the animal model of sepsis was constructed by intraperitoneal injection of lipopolysaccharide (LPS) dissolved in physiological saline at 12.5 mg/kg (LPS group); and metformin (MetChemExpress; Monmouth Junction, NJ, USA) dissolved in physiological saline was injected intraperitoneally at 25 mg/kg at 1 h after completion of the LPS injection (MET group). The animal body temperature was recorded before and 18 h after LPS injection with an electronic rectal thermometer. This study was conducted in compliance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals, and the Ethical Review Committee of Zhengzhou University approved the experiments.

**Liver tissue and plasma sample collection**

The mice were anesthetized using 0.6% pentobarbital sodium (40 mg/kg of body weight, IP) at 24 hours after LPS injection. The blood was collected with an anticoagulant tube containing ethylenediaminetetraacetic acid (EDTA) from retro-orbital sinus and centrifuged (2,500 rpm, 10 min, room temperature) to collect plasma, which was then stored at −80°C for subsequent assays. The thorax of the mouse was opened to expose the thoracic cavity and cut the postcava, followed by the perfusion needle insertion into the apical region. A volume (approximately 100 mL) of pre-
cooled saline was rapidly pushed into the left ventricle and aorta. Liver tissues were removed and stored at – 80°C and fixed in 4% paraformaldehyde for subsequent experiments.

**Biochemical analysis**

Plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using biochemical kits per manufacturer’s instructions (Nanjing Jiancheng Bioengineering Institute, China).

**Enzyme-linked immunosorbent assay (ELISA) for cytokines**

Mouse ELISA Kits (CSB-E04741m; CSB-E04639m, CUSABIO, Wuhan, China) were used to determine plasma tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6) levels. Briefly, the optical density (OD) of the plasma sample was measured at 450 nm to quantify values of TNF-α and IL-6 by comparing relative to each standard curve respectively.

**Histological and apoptosis analysis of mice liver**

Hematoxylin and eosin (H&E) staining was performed to observe the degree of inflammatory cell infiltration. The liver tissue was embedded in paraffin and sliced into 3–5 μm sections. The H&E stained sections were observed under a light microscope. We quantified edema and hemorrhage within the liver tissue. To assess the liver lesions better, we chose three sections and three regions within each section to obtain the mean score as the final score for each animal. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end-labeling (TUNEL) staining assay (KeyGen, Nanjing, China) was used to label the fragmented DNA of apoptotic cells (brown nuclear staining) according to the manufacturer’s instructions.

**Western blot assay**

The proteins from each liver tissue sample were extracted using a high radioimmunoprecipitation assay (RIPA) buffer (Solarbio Science & Technology Co., Ltd.), and a bicinchoninic acid (BCA) protein assay kit (Solarbio Science & Technology Co., Ltd,) was used to determine the concentrations. A small amount of the total protein (30 μg) per sample was subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and electrophoretically transferred onto a polyvinylidene fluoride (PVDF) membrane (Immobilon®-P, USA). The membrane was incubated with 5% (w/v) skim milk in the tris-buffered saline with Tween-20 (1%) for 90 min at room temperature, and incubated overnight at 4°C with different primary antibodies (anti-AMPK (CST, Boston, USA; 1:1000), anti-p-AMPK, anti-PGC-1α, anti-PDK1, anti-AKT, anti-p-AKT, anti-MAPK p38, anti-p-p38, and anti-HIF-1α from CST, Boston, USA (1:1000 and anti-HMGBlanti-TNF-α, anti-GAPDH from Proteintech, Wuhan, China (1:5000)). The membrane was then washed three times and incubated with goat anti-rabbit IgG-HRP secondary antibody (Cwbio, Beijing, China 1:5000) for 90 min at room temperature. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal reference protein for total protein blotting. The process of Western blot has been described previously [22]. The Image J software was used to quantify the densitometry of bands.

**Reverse transcription-polymerase chain reaction analysis**

The experimental process according to describe earlier [23]. TRizol reagent (Takara, Tokyo, Japan) was used to extract total RNA from the liver. The concentration and purity of RNA were quantified by ultraviolet spectroscopy. The TaqMan Reverse Transcription Kit (UE, Suzhou, China) and a Gene Amp polymerase chain reaction (PCR) system were used for generating cDNA. Polymerase chain reaction using qPCR SYBR Green Master Mix (Yeasen, Shanghai, China). All the amplifications were repeated three times. Oligonucleotide primer sequences were: Caspase-1 forward primer: CTGAGGGCAAAAGAG GAAGCA, reverse primer: AACTTGAGCTCCA ACCCTCG. Hypoxia-inducible factor-1a (HIF-1a) forward primer: CAGCCAGAAAGTCTCTTGA, reverse primer: TGCCTTAGCAGTTGGCTGTTT. Interleukin 6 (IL-6) forward primer: TGATGCA CTTGCAGAAAAA, reverse primer: ACCAGAG AAATTTTCAATAGGC. Pyruvate dehydrogenase
kinase-1 (PDK1) forward primer: GGATCTGTCAACGAGCAA, reverse primer: AGGCCGTATATGGGCAATCC. Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha (PGC-1α) forward primer: CAGGAACACGAGCAGAGACA, reverse primer: TGGAAGAACAGATGTGCC. Tumor necrosis factor-α (TNF-α) forward primer: CCACCAGCTTCGCAGTCAACA, reverse primer: AGGCTCTGGCGCATAGAAGT. C–C motif chemokine ligand 3 (CCL3) forward primer: ACCATGACACTCTGCAACCA, reverse primer: GTGGAATCTTCGGGCTGTCTAG. C–C motif chemokine ligand 4 (CCL4) forward primer: CATGAAAGCTCTGGTGCAGTGAC, reverse primer: GAAAGACGAGAGGAATGGGAG. C–C motif chemokine ligand 7 (CCL7) forward primer: CTGCTTCAGCTCAGCAAGTG, reverse primer: GCCAACGAGGAAAGGGGTCTGGGCCATAGAACT. C–C motif chemokine ligand 8 (CCL8) forward primer: TCTTCCGGCTGTAG, reverse primer: TGTCTGCAGCTTCAGCATCCAGTG. β-actin (actin, beta) forward primer: AGTGTGACGTTGACACTCCGT, reverse primer: GCACGTCACTTCAACTCCGC. β-actin was used as an endogenous control, and each sample was normalized according to its β-actin content. The gene expression data were set to 100% relative to the control group. The relative quantification of the target gene mRNA expression levels was calculated by the $2^{-\Delta\Delta Ct}$ method.

Statistical evaluation

All data were presented as mean ± standard. The Student t-test (two-group comparisons) and one-way ANOVA (three-group comparisons) were used to determine differences. We performed Tukey’s post hoc test when there was a significant difference in ANOVA analysis. Differences were considered statistically significant at $P < 0.05$. The graphs were presented using GraphPad Prism 8.0.

Results

In the present study we hypothesized that metformin may alleviate liver injury in aged septic mice via the AMPK–PGC1α axis. After performing the aged septic mice model, blood samples and liver tissue were collected for biochemical analysis, histopathology, reverse transcription-polymerase chain reaction (RT–PCR), and Western blot assays. We investigated the therapeutic effects of metformin in aged septic mice.

The effects of metformin on body temperature and liver dysfunction in septi-c aged mice

The body temperature (BT) of mice was recorded before and 18 h after the LPS injection. The body temperature of LPS-administered mice was significantly lower than group C, with a mean decrease of 6.38°C (Figure 1(a), $P < 0.05$). However, the body temperature of metformin-treated mice decreased by a mean of 4.02°C. The data indicated no statistically significant differences in the BT changes between the LPS-administered and the metformin-treated mice. However, metformin had a certain reversal effect on hypothermia in the septic aged mice. In addition, the level of plasma ALT of the control mice increased significantly from 11.17 U/L to 58.11 U/L in the LPS-administered mice; whereas its level decreased to 18.86 U/L in the metformin-treated septic aged mice. Metformin also reduced the plasma AST levels (Figure 1(b), $P < 0.05$). Meanwhile, we quantified the contents of TNF-α and IL-6 in the plasma of three groups of mice. As expected, the contents of these two pro-inflammatory cytokines showed a significant decrease after metformin treatment (Figure 1(c), $P < 0.05$). The results demonstrated the beneficial effects of metformin in reversing sepsis-associated hypothermia and liver dysfunction in septic aged mice.

Metformin ameliorated the pathological liver damage and cell apoptosis in septic aged mice

We performed the H&E staining of the liver tissue to evaluate the organ pathological injury and hepatocyte apoptosis caused by LPS-induced sepsis. The LPS administration group showed significant destruction of hepatic lobular structures, edema, inflammatory cell infiltration, and hepatic hemorrhage compared to the control group, and these observations were mitigated in the metformin-treated mice (Figure 2(a)). We further conducted the TUNEL assay to confirm the role of metformin in hepatocytes apoptosis. The results showed that the number of apoptotic cells in the
liver of mice in the LPS group was significantly increased compared with the C group; however, they were distinctly decreased in the MET group (Figure 2(b)). The percentage of apoptotic cells in the LPS group was markedly higher than the C group, and metformin administration substantially alleviated cell apoptosis (Figure 2(c), $P < 0.05$). These results were consistent with the results of H&E staining. Thus, metformin ameliorated liver pathological damage and cell apoptosis in septic aged mice.

**Metformin attenuated liver injury and inflammatory response in septic aged mice**

Overwhelming inflammatory response derived from a cytokine storm is the main cause of organ dysfunction and lethality in sepsis [24]. We analyzed the expressions of relevant cytokines and chemokines in septic aged mice. We found LPS-related sepsis visibly upregulated the mRNA expression of IL-6, TNF-α, pyrocytosis-related factors (such as caspase-1), hypoxia-inducible factors...
such as HIF1-α), and chemokines. In contrast, metformin administration markedly reduced the mRNA levels of these cytokines and chemokines compared with the LPS group (Figure 3(a-h), P < 0.05). It was also observed that the mRNA level of PGC1-α decreased in the LPS-induced septic aged mice compared to the C group, whereas metformin reversed the LPS-induced decreased expression of PGC1-α (Figure 3(i), P < 0.05).

Studies have shown that suppression of PGC1-α reprogrammed the metabolic energy and altered mitochondrial morphology, while reactivation of PGC-1 reduced oxidative stress and improved organ function [25,26]. Next, we measured changes in relevant target proteins, such as PGC1-α, PDK1, HIF-1α, and related inflammatory factors, to understand the potential mechanisms by which metformin attenuated inflammatory response and liver injury in aged septic

Figure 2. Effects of metformin on liver injury and inflammation in septic, aged mice. (a) H&E staining indicated the presence of inflammatory infiltrates, edema, and hemorrhage in the LPS group; however, metformin treatment ameliorated these abnormalities (scale bars = 100 μm/50 μm). (b) The TUNEL assay results in the three groups (scale bars = 50 μm). (c) The percentage of apoptotic cells in the three groups. (n = 3 per group).
We observed that LPS administration activated the AKT signaling pathway proteins such as MAPK p38, TNF-α, and HMGB1. As expected, metformin attenuated inflammation and liver injury by activating the AMPK phosphorylation that inhibited the AKT signal activation. Moreover, metformin reversed the PGC1-α decrease and the PDK1 and HIF-1α increase caused by LPS (Figure 4, P < 0.05). These results clearly indicated that metformin attenuates liver injury and inflammatory responses, possibly by activating the AMPK–PGC1-α axis in aged septic mice.

**Discussion**

This study suggested that metformin may mitigate inflammatory response and liver injury via the AMPK–PGC1-α axis in septic aged mice. Our findings imply metformin as a potential therapeutic option for moderating inflammatory response on sepsis-associated liver injury in aged mice. Most animal studies on sepsis employed young animals. Previous studies have reported an increased incidence of sepsis and mortality with age due to increased plasma inflammatory cytokine levels and local inflammatory responses in aged mice [27–29]. Studies on adult animals have restricted our knowledge and understanding of treatment strategies for elderly patients with sepsis. Therefore, we used aged mice in this study to establish a sepsis model and to evaluate the effect of metformin on sepsis-related liver injury.

A study reported that metformin alleviated liver dysfunction by decreasing hepatic lipid accumulation and serum levels of ALT/AST in ob/ob mice [30]. As known, the ALT/AST activities are appropriate tests for estimating the extent of liver injury. Similarly, our results revealed that metformin treatment, compared to LPS administration, markedly decreased the ALT/AST levels in circulation, suggesting a favorable effect of metformin in protecting the liver.
Recently, a study reported that elevated BT of patients with severe sepsis or septic shock on ICU admission predicted increased survival [31]. Yet another study reported that mortality in non-elderly patients with sepsis decreased with fever and increased with hypothermia, whereas no correlation between mortality and BT was found in elderly patients [32]. Our study found that metformin administration could reverse the hypothermia caused by LPS in aged mice, although there was no statistical difference. The interaction of BT, age, and other confounding factors on the

Figure 4. (a) Protein expression levels among C group, LPS group, and MET group. (b–d) The level of protein expression in the activated AMPK/Akt/p38 signaling pathway among the three groups. (e) The expression of target protein in the three groups. (n = 3 per group).
prognosis of sepsis had no noticeable results. The metformin mechanism on BT of septic mice needs to be further explored.

Our research is consistent with the previous report that metformin protects against sepsis in rats [20], which may be attributed to its anti-inflammatory effects and reduction in neutrophil accumulation. We found that metformin activated the AMPK signaling pathway and reversed the decrease in PGC1-α expression and the increase in PDK1 expression in the liver of aged septic mice. Additionally, the related inflammatory factors, such as TNF-α, HMGB1, were downregulated in the MET group. We also found that metformin reduced LPS-induced elevated expression of mRNA for pro-inflammatory factors, such as TNF-α, IL-6, caspase-1, and HIF1-α. These findings were in line with previous studies [33,34] that showed AMPK could limit the activation of downstream inflammatory targets in various situations. We observed that metformin reduced the increased mRNA levels of chemokines caused by LPS. Chemokines play a crucial role in recruiting inflammatory cells in sepsis that contribute to neutrophil infiltration leading to multiple organ dysfunction and failure [35]. However, the exact underlying mechanisms remain to be further explored.

When sepsis occurs, the immune response caused by the invading pathogen fails to restore homeostasis, eventually leading to a pathological syndrome characterized by persistent hyperinflammation and immunosuppression [36]. Cellular bioenergetics and metabolism play a key role in the regulation of immunity during acute inflammation. Inflammation in sepsis involves both adaptive and innate immunity [37], and the early immune response requires a high-energy metabolic state supported by glucose-dependent ATP production, mainly provided by glycolysis.

Metformin inducing the activation of the energy metabolism switch AMPK, has been well documented [38]. The AMPK could inhibit bioenergetic reprogramming (aerobic glycolysis) in macrophages and monocytes [39]. AMPK signaling pathway plays a substantial role in cell cycle, energy metabolism reprogramming, and autophagy [40–42]; during hypoxia and oxidative stress, AMPK is activated and promotes metabolic reprogramming.

The transcriptional coactivator, PGC-1α, mediates many biological processes related to energy metabolism, especially the control of mitochondrial biogenesis and oxidative metabolism [43,44]. The suppressed PGC-1α caused by LPS administration results in cardiac energy metabolic reprogramming and functional derangements [26]. Meanwhile, the increased PGC-1α expression could alleviate endotoxin-induced acute kidney injury, mitochondrial injury, and superoxide accumulation [45]. This study found that metformin reversed the LPS-induced down-regulation of PGC-1α expression in aged mice. A previous study showed that cardiac AMPK mediates PGC-1α levels by post-myocardial infarction [46]. In addition, activating the AMPK–PGC-1α signaling pathway could inhibit apoptosis and enhance energy metabolism [47]. Our results were in line with the previous findings.

PDK1 was reported as the downstream regulator of PGC1-α that improved inflammation and metabolism by inhibiting the PDK1 expression [48]. Furthermore, a previous study showed that the PDK activity blockage in mice represses macrophage M1 polarization, reducing adipose tissue inflammation and insulin resistance [49]. PDK1 enhanced glycolysis in macrophages co-incubated with LPS, thereby promoting M1 polarization of macrophages [50]. Several studies showed that glycolysis regulates activation of M1 macrophages and other immunocytes, such as dendritic cells [51–55].

It is well known that HIF-1α is the primary glycolysis-regulating molecule. Cells respond to hypoxia through HIF-1α mediated upregulation of glucose transport proteins and glycolysis-related enzymes, such as phosphofructose kinase and PDK1 [56], which interrupt pyruvate dehydrogenase enzyme and reduce the mitochondrial glucose oxidation in the tricarboxylic acid cycle.

Metformin inhibited inflammatory infiltration by reducing the recruitment of macrophages [57], and decreased expression of inflammatory factors, such as HMGB1, IL-1β, and IL-6 [58]. Earlier studies demonstrated that metformin reduced mortality in a mouse model of lethal endotoxemia by inhibiting HMGB1 release; inhibition of NF-κB-induced TNF-α activation and AMPK activation were the mechanisms contributing to the
protective effects [59,60]. Our results suggest that AMPK upregulated the PGC1-α expression, which then inhibited PDK1 and HIF-1α expression.

There are some limitations in the present study. We only conducted in vivo experiments and lacked in vitro functional experiments. The immunomodulatory effect of metformin seems to have a potential role in anti-sepsis treatment, but the exact mechanism remains to be studied and elucidated in the future.

**Conclusion**

Our findings showed that metformin attenuated liver injury and inflammatory response in LPS-induced septic aged mice. Mechanistically, metformin may exert a protective effect on liver injury in septic aged mice via the AMPK–PGC-1α axis. Our study may provide new insights on metformin-based strategy for sepsis treatment in the elderly, although the mechanism requires further research and confirmation.

**Acknowledgements**

This study was supported by the United Fund of National Natural Science Foundation of China (Grant No. U2004110) and the 2021 youth talent promotion project in Henan Province (Grant No. 2021HYTP053). We thank Hongyi Li, Yan Yan, Zhu Yanhui, and Liu Huan for assisting with the animal experiments. We also thank the Laboratory of School of Life Sciences, Zhengzhou University in assisting with partial completion of our work.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This study was supported by the Joint Foundation of the National Natural Science Foundation of China (Grant No. U2004110) and the Henan Province 2021 Young Talent Promotion Program (Grant No. 2021HYTP053).

**References**

[1] Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810.

[2] Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862–874.

[3] Vincent J-L, Marshall JC, Namendys-Silva SA, et al. Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit. Lancet Respir Med. 2014;2(5):380–386.

[4] Yahav D, Eliakim-Raz N, Leibovici L, et al. Bloodstream infections in older patients. Virulence. 2016;7(3):341–352.

[5] Skogberg K, Lytyikäinen O, Ollig J, et al. Population-based burden of bloodstream infections in Finland. Clin Microbiol Infect. 2012;18(6):E170–176.

[6] Brun-Buisson C, Meshaka P, Pinton P, et al. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med. 2004;30(4):580–588.

[7] Wester AL, Dunlop O, Melby KK, et al. Age-related differences in symptoms, diagnosis and prognosis of bacteremia. BMC Infect Dis. 2013;13:346.

[8] Lee CC, Chen SY, Chang JJ, et al. Comparison of clinical manifestations and outcome of community-acquired bloodstream infections among the oldest old, elderly, and adult patients. Medicine (Baltimore). 2007;86(3):138–144.

[9] Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med. 2006;34(1):15–21.

[10] Komorowski M, Celi LA, Badawi O, et al. The artificial intelligence clinician learns optimal treatment strategies for sepsis in intensive care. Nat Med. 2018;24(11):1716–1720.

[11] Ankawi G, Neri M, Zhang J, et al. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls. Crit Care. 2018;22(1):262.

[12] Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. Bmj. 2016;353:i1585.

[13] Eikawa S, Nishida M, Mizukami S, et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015;112(6):1809–1814.

[14] Cameron AR, Morrison VL, Levin D, et al. Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res. 2016;119(5):652–665.

[15] Soukas AA, Hao H, Wu L. Metformin as anti-aging therapy: is it for everyone?. Trends Endocrinol Metab. 2019;30(10):745–755.

[16] Malik F, Mehdi SF, Ali H, et al. Is metformin poised for a second career as an antimicrobial?.. Diabetes Metab Res Rev. 2018;34(4):e2975.

[17] Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4(1):2192.

[18] Lee Y, Park BH, Bae EJ. Compound C inhibits macrophage chemotaxis through an AMPK-independent
mechanism. Biochem Biophys Res Commun. 2016;469(3):515–520.

[19] Liang H, Ding X, Sun T, et al. Metformin mitigated glucocorticoid resistance through activating AMPK in septic rat. Eur Respir J. 2019;54(suppl 63):2269.

[20] Ghavimi H, Sheidaei S, Vaez H, et al. Metformin-attenuated sepsis-induced oxidative damages: a novel role for metformin. Iran J Basic Med Sci. 2018;21(5):469–475.

[21] Liang H, Ding X, Li L, et al. Association of predmision metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies. Crit Care. 2019;23(1):50.

[22] Ding XF, Liang HY, Sun JY, et al. Adipose-derived mesenchymal stem cells ameliorate the inflammatory reaction in CLP-induced septic acute lung injury rats via sTNFR1. J Cell Physiol. 2019;234:16582–16591.

[23] Liang H, Ding X, Yu Y, et al. Adipose-derived mesenchymal stem cells ameliorate acute liver injury in rat model of CLP-induced-sepsis via sTNFR1. Exp Cell Res. 2019;383(1):111465.

[24] Fajenbaum DC, June CH, Longo DL. Cytokine Storm. N Engl J Med. 2020;383(23):2255–2273.

[25] Casemayou A, Fournel A, Bagattin A, et al. Hepatocyte nuclear Factor-1β controls mitochondrial cholesterol in renal tubular cells. J Am Soc Nephrol. 2017;28(11):3205–3217.

[26] Schilling J, Lai L, Sambandam N, et al. Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor γ coactivator-1 signaling. Circ Heart Fail. 2011;4(4):474–482.

[27] Starr ME, Ueda J, Takahashi H, et al. Age-dependent vulnerability to endotoxemia is associated with reduction of anticoagulant factors activated protein C and thrombomodulin. Blood. 2010;115(23):4886–4893.

[28] Nacionales DG, Gentile LF, Vanzant E, et al. Aged mice are unable to mount an effective myeloid response to sepsis. J Immunol. 2014;192(2):612–622.

[29] Turnbull IR, Clark AT, Stromberg PE, et al. Effects of aging on the immunopathologic response to sepsis. Crit Care Med. 2009;37(3):1018–1023.

[30] Song YM, Lee YH, Kim JW, et al. Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway. Autophagy. 2015;11(1):46–59.

[31] Inghammar M, Sunden-Cullberg J, Sarkar A. Prognostic significance of body temperature in the emergency department vs the ICU in Patients with severe sepsis or septic shock: a nationwide cohort study. PLoS One. 2020;15(12):e0243990.

[32] Shimazui T, Nakada T-A, Walley KR, et al. Significance of body temperature in elderly patients with sepsis. Crit Care. 2020;24(1):387–387. DOI:10.1186/s13054-020-02976-6.

[33] Rutherford C, Speirs C, Williams JJ, et al. Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling. Sci Signal. 2016;9(453):ra109.

[34] Ou Z, Kong X, Sun X, et al. Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice. Brain Behav Immun. 2018;69:351–363.

[35] Castanheira F, Borges V, Sônego F, et al. The atypical chemokine receptor ACKR2 is protective against sepsis. Shock. 2018;49(6):682–689.

[36] van der Poll T, van de Veerdonk FL, Scicluna BP, et al. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17(7):407–420.

[37] Hotchkiss RS, Opal S. Immunotherapy for sepsis—a new approach against an ancient foe. N Engl J Med. 2010;363(1):87–98.

[38] Foretz M, Guigas B, Bertrand L, et al. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20(6):953–966.

[39] Huang J, Liu K, Zhu S, et al. AMPK regulates immu-nometabolism in sepsis. Brain Behav Immun. 2018;72:89–100.

[40] Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond). 2008;32(Suppl 4):S7–12.

[41] Aucilli FR, Ross FA, Ikematsu N, et al. Oxidative stress activates AMPK in cultured cells primarily by increasing cellular AMP and/or ADP. FEBS Lett. 2014;588(18):3361–3366.

[42] Zhao Y, Hu X, Liu Y, et al. ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. Mol Cancer. 2017;16(1):79.

[43] Boström P, Wu J, Jédrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–468.

[44] Gleyzer N, Scarpulla RC. PGC-1-related coactivator (PRC), a sensor of metabolic stress, orchestrates a redox-sensitive program of inflammatory gene expression. J Biol Chem. 2011;286(46):39715–39725.

[45] Zhang M, Dong W, Li Z, et al. Effect of forkhead box O1 in renal tubular epithelial cells on endotoxin-induced acute kidney injury. Am J Physiol Renal Physiol. 2021;320(3):F262–F272.

[46] Quan N, Wang L, Chen X, et al. Sestrin2 prevents age-related intolerance to post myocardial infarction via AMPK/PGC-1α pathway. J Mol Cell Cardiol. 2018;115:170–178.

[47] Jiang B, Yang YJ, Dang WZ, et al. Astragaloside IV reverses simvastatin-induced skeletal muscle injury by activating the AMPK-PGC-1α signalling pathway. Phytother Res. 2020;34(5):1175–1184.

[48] Zuo Q, He J, Zhang S, et al. PPARy Coactivator-1α suppresses metastasis of hepatocellular carcinoma by inhibiting warburg effect by PPARγ-Dependent WNT/
β-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 axis. Hepatology. 2021;73(2):644–660.

[49] Min BK, Park S, Kang HJ, et al. Pyruvate dehydrogenase kinase is a metabolic checkpoint for polarization of macrophages to the M1 phenotype. Front Immunol. 2019;10:944.

[50] Tan Z, Xie N, Cui H, et al. Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism. J Immunol. 2015;194(12):6082–6089.

[51] Pearce EL, Poffenberger MC, Chang CH, et al. Fueling immunity: insights into metabolism and lymphocyte function. Science. 2013;342(6155):1242454.

[52] Chang CH, Curtis JD, Maggi LB Jr., et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153(6):1239–1251.

[53] Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity. 2013;38(4):633–643.

[54] Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature. 2013;496(7444):238–242.

[55] Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ. 2008;15(4):621–627.

[56] Liu Q, Tong D, Liu G, et al. Metformin inhibits prostate cancer progression by targeting tumor-associated inflammatory infiltration. Clin Cancer Res. 2018;24(22):5622–5634.

[57] Park MJ, Moon SJ, Baek JA, et al. Metformin augments anti-inflammatory and chondroprotective properties of mesenchymal stem cells in experimental osteoarthritis. J Immunol. 2019;203(1):127–136.

[58] Tsai K, Jang HJ, Nizamutdinova IT, et al. Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol. 2011;162(7):1498–1508.

[59] Hattori Y, Suzuki K, Hattori S, et al. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006;47(6):1183–1188.